Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.
4,400 dedicated employees – more than 75 years of experience in developing innovative medicines – a fully integrated setup including R&D and five manufacturing sites.
These are some of the key figures that have helped us become the leading pain management company in Europe and Latin America.
For the latest insights into our people, our products and our ambitious plans to move closer to our vision of A World Free of Pain,
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.
Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.
Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA
Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxinGrünenthal announced that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX).
RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile.
Grünenthal starts global clinical Phase III programme for resiniferatoxin (RTX)
Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.
Join forces.
Make an impact.
Innovate for a world free of pain.
